Healthcare >> CEO Interviews >> May 27, 2003
CHRISTOPHER J. SEARCY is Vice President of Corporate Development at
Nektar Therapeutics. He joined Nektar when it was still named Inhale in
1996. Previously, Dr. Searcy was the Vice President of Business
Development of GalaGen, Inc., an oral antibody company focusing on human
gastrointestinal tract infections. From 1985 to 1995, Dr. Searcy held
various positions in registration and regulatory affairs, clinical
research and marketing at Pfizer Inc. In his last position at Pfizer, he
was the Director of Licensing and Development. Dr. Searcy holds a BS in
Pharmacy and a PharmD both from the University of Minnesota, and an MBA
from the University of Pennsylvania, Wharton School. Profile
you explain the name change?
Dr. Searcy: Nektar, formerly Inhale Therapeutic Systems, Inc.,
provides novel drug delivery
